OneAscent Financial Services LLC Has $1.01 Million Stock Holdings in Johnson & Johnson $JNJ

OneAscent Financial Services LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 60.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 5,438 shares of the company’s stock after selling 8,415 shares during the quarter. OneAscent Financial Services LLC’s holdings in Johnson & Johnson were worth $1,008,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Clayton Financial Group LLC acquired a new stake in Johnson & Johnson in the 3rd quarter valued at $28,000. Evolution Wealth Management Inc. bought a new position in shares of Johnson & Johnson in the 2nd quarter valued at about $27,000. Semmax Financial Advisors Inc. increased its position in shares of Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after acquiring an additional 72 shares during the last quarter. GFG Capital LLC bought a new stake in Johnson & Johnson during the second quarter worth about $35,000. Finally, Signature Resources Capital Management LLC boosted its position in Johnson & Johnson by 262.9% during the third quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock valued at $47,000 after purchasing an additional 184 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Price Performance

Shares of JNJ opened at $204.47 on Friday. The company’s 50-day moving average is $202.87 and its 200-day moving average is $184.52. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. The firm has a market capitalization of $492.62 billion, a PE ratio of 19.74, a PEG ratio of 2.11 and a beta of 0.34. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $215.18.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. The business had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 2.5%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the company. Johnson Rice set a $190.00 price objective on Johnson & Johnson and gave the stock a “hold” rating in a research note on Wednesday, October 22nd. Scotiabank assumed coverage on shares of Johnson & Johnson in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $230.00 price target on the stock. Citigroup lifted their price objective on shares of Johnson & Johnson from $215.00 to $232.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Bank of America upped their target price on shares of Johnson & Johnson from $204.00 to $220.00 and gave the company a “neutral” rating in a report on Monday, December 15th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a research note on Friday, October 31st. Four research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $213.33.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Barclays raised its JNJ price target on strength in key drugs, signaling analyst confidence in the company’s mid-term revenue drivers. Barclays Raises Johnson & Johnson (JNJ) Target on Strength in Key Drugs
• Positive Sentiment: Deal with the Trump administration gives JNJ tariff exemptions and accelerates a reported ~$55 billion plan to expand U.S. manufacturing — this reduces tariff risk, improves supply-chain resilience and could support margins over time. J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve
• Positive Sentiment: Clinical and product-development catalysts: mid-stage success for nipocalimab in SLE and J&J MedTech’s Ottava surgical robot submission to the FDA could drive future revenue and sentiment if approvals/commercialization progress. J&J succeeds in mid-stage trial for SLE therapy Johnson & Johnson MedTech submits Ottava surgical robot to FDA
• Neutral Sentiment: Sector tailwind: healthcare stocks have been rallying and JNJ sits in many health-care ETFs, which can provide passive-buying support independent of company-specific news. This ETF Is Proof That the Healthcare Rebound Is Real
• Neutral Sentiment: Partnerships and collaborations (e.g., Lexeo on cardiac gene therapy) expand J&J’s pipeline exposure but are longer-term and incremental to near-term earnings. Lexeo Therapeutics Announces Research Collaboration with Johnson & Johnson
• Negative Sentiment: JNJ agreed to cut U.S. drug prices as part of the government deal — that creates near- and medium-term revenue/price pressure for affected medicines and is a headline risk for investors focused on margins. Johnson & Johnson reaches deal with US government to lower drug prices
• Negative Sentiment: Zacks trimmed several near-term EPS estimates (Q1–Q4 and FY2027) marginally — this reflects some analyst caution after the pricing agreement and contributes to downward pressure on the stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.